Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedLicence not statedFuture Oncology

Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective

  1. 1Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy
  2. 2Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy

Related

  1. Targeting the PI3K/AKT/mTOR pathway in endocrine-resistant, hormone receptor-positive, HER2-negative, advanced breast cancer
    Antonino Glaviano, Rachel O. Abelman, Andreas Varkaris +8
    eClinicalMedicinePeer-reviewedCC BY-NC-ND 4.0General medicineCrossref
  2. CDK4/6 Inhibitors in the Treatment of Advanced ER/PR-Positive, HER2-Negative Breast Cancer: An Updated Single-Center Analysis of Real-World Data
    Anna-Christina Rambow, Tim Jannik Schröder, Gudrun Wagenpfeil +6
    Breast care (Basel, Switzerland)Peer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  3. Neoadjuvant Chemotherapy Increases Genomic Radioresistance in Hormone Receptor–positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Implications for Radiation Sensitivity Index/Genomic-Adjusted Radiation Dose–Guided Radiation Therapy Personalization
    Pierre Loap, Gilles Crehange, Youlia Kirova
    Advances in Radiation OncologyPeer-reviewedCC BY 4.0Full textOncologyPMCEurope PMC
  4. Hormone receptor–positive HER2-negative oligometastatic breast cancer: prognostic stratification and pattern of progression
    Jean-Louis Lacaze, Bastien Cabarrou, Thibaut Cassou-Mounat +10
    The OncologistPeer-reviewedCC BY-NC 4.0Full textOncologyPMC
  5. Integrated CDK4/6 inhibitor resistance and primary-metastatic discordance in hormone receptor-positive/HER2-negative metastatic breast cancer: a translational framework focused on invasive ductal carcinoma with gastric metastasis.
    Minyi Cheng, Dongqing Wang, Yingyi Lin +4
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
BibTeX
@article{matera2026gedatolisib,
  title = {{Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective}},
  author = {Letizia Matera and Julian David Etessami and Carmine Valenza and Giuseppe Curigliano},
  journal = {Future Oncology},
  year = {2026},
  month = oct,
  doi = {10.1080/14796694.2026.2742759},
  url = {https://doi.org/10.1080/14796694.2026.2742759},
}
RIS
TY  - JOUR
TI  - Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective
AU  - Letizia Matera
AU  - Julian David Etessami
AU  - Carmine Valenza
AU  - Giuseppe Curigliano
PY  - 2026
DA  - 2026/10/05
JO  - Future Oncology
DO  - 10.1080/14796694.2026.2742759
UR  - https://doi.org/10.1080/14796694.2026.2742759
SN  - 1479-6694
SN  - 1744-8301
ER  -